Latest Krensavage Asset Management, LLC Stock Portfolio
Krensavage Asset Management, LLC Performance:
2025 Q4: 18.13%YTD: 55.92%2024: 4.72%
Performance for 2025 Q4 is 18.13%, and YTD is 55.92%, and 2024 is 4.72%.
About Krensavage Asset Management, LLC and 13F Hedge Fund Stock Holdings
On 2026-02-18, the fund reported it's updated stock portfolio. In the 13F Holdings report, Krensavage Asset Management, LLC reported an equity portfolio of $283.1 Millions as of 31 Dec, 2025.
The top stock holdings of Krensavage Asset Management, LLC are UTHR, ENTA, BMRN. The fund has invested 15.7% of it's portfolio in UNITED THERAPEUTICS CORP and 15.4% of portfolio in ENANTA PHARMACEUTICALS INC.
They significantly reduced their stock positions in GSK PLC-SPON ADR (GSK), ALKERMES PLC (ALKS) and SUPERNUS PHARMACEUTICALS INC (SUPN). Krensavage Asset Management, LLC opened new stock positions in ULTRAGENYX PHARMACEUTICAL IN (RARE). The fund showed a lot of confidence in some stocks as they added substantially to ENANTA PHARMACEUTICALS INC (ENTA), BIOMARIN PHARMACEUTICAL INC (BMRN) and BIONTECH SE-ADR (BNTX).
The top stock holdings of Krensavage Asset Management, LLC are UTHR, ENTA, BMRN. The fund has invested 15.7% of it's portfolio in UNITED THERAPEUTICS CORP and 15.4% of portfolio in ENANTA PHARMACEUTICALS INC.
They significantly reduced their stock positions in GSK PLC-SPON ADR (GSK), ALKERMES PLC (ALKS) and SUPERNUS PHARMACEUTICALS INC (SUPN). Krensavage Asset Management, LLC opened new stock positions in ULTRAGENYX PHARMACEUTICAL IN (RARE). The fund showed a lot of confidence in some stocks as they added substantially to ENANTA PHARMACEUTICALS INC (ENTA), BIOMARIN PHARMACEUTICAL INC (BMRN) and BIONTECH SE-ADR (BNTX).
Krensavage Asset Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Krensavage Asset Management, LLC made a return of 18.13% in the last quarter. In trailing 12 months, it's portfolio return was 55.92%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| ultragenyx pharmaceutical in | 3,442,000 |
New stocks bought by Krensavage Asset Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| enanta pharmaceuticals inc | 30.83 |
| biomarin pharmaceutical inc | 29.43 |
| biontech se-adr | 25.4 |
Additions to existing portfolio by Krensavage Asset Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| gsk plc-spon adr | -64.4 |
| alkermes plc | -48.12 |
| supernus pharmaceuticals inc | -13.75 |
| avadel pharmaceuticals | -10.46 |
| united therapeutics corp | -6.52 |
| exelixis inc | -4.82 |
Krensavage Asset Management, LLC reduced stake in above stock
Sold off
Sector Distribution
Krensavage Asset Management, LLC has about 78.6% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 78.6 |
| Others | 21.4 |
Market Cap. Distribution
Krensavage Asset Management, LLC has about 51.5% of it's portfolio invested in the large-cap and mega-cap stocks.
- LARGE-CAP
- UNALLOCATED
- SMALL-CAP
- MID-CAP
| Category | % |
|---|---|
| LARGE-CAP | 51.5 |
| UNALLOCATED | 21.4 |
| SMALL-CAP | 20.3 |
| MID-CAP | 6.6 |
Stocks belong to which Index?
About 33% of the stocks held by Krensavage Asset Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
- S&P 500
| Index | % |
|---|---|
| Others | 67 |
| RUSSELL 2000 | 25.9 |
| S&P 500 | 7.1 |
Krensavage Asset Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Krensavage Asset Management, LLC
Krensavage Asset Management, LLC has 18 stocks in it's portfolio. About 87.1% of the portfolio is in top 10 stocks. ALKS proved to be the most loss making stock for the portfolio. ENTA was the most profitable stock for Krensavage Asset Management, LLC last quarter.
Last Reported on: 18 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALKS | alkermes plc | 1.07 | 107,822 | 3,017,000 | reduced | -48.12 | ||
| BIIB | biogen inc | 0.62 | 10,000 | 1,760,000 | unchanged | 0.00 | ||
| BMRN | biomarin pharmaceutical inc | 11.02 | 524,786 | 31,188,000 | added | 29.43 | ||
| BNTX | biontech se-adr | 3.35 | 99,523 | 9,475,000 | added | 25.4 | ||
| CAH | cardinal health inc | 5.35 | 73,745 | 15,155,000 | unchanged | 0.00 | ||
| ENTA | enanta pharmaceuticals inc | 15.41 | 2,766,390 | 43,626,000 | added | 30.83 | ||
| EOLS | evolus inc | 0.23 | 100,000 | 665,000 | unchanged | 0.00 | ||
| EXEL | exelixis inc | 7.64 | 493,526 | 21,631,000 | reduced | -4.82 | ||
| GSK | gsk plc-spon adr | 1.68 | 96,729 | 4,744,000 | reduced | -64.4 | ||
| JAZZ | jazz pharmaceuticals plc | 10.08 | 167,816 | 28,529,000 | unchanged | 0.00 | ||
| RARE | ultragenyx pharmaceutical in | 1.22 | 149,634 | 3,442,000 | new | |||
| REGN | regeneron pharmaceuticals | 1.09 | 4,000 | 3,087,000 | unchanged | 0.00 | ||
| SNY | sanofi-adr | 5.54 | 323,946 | 15,698,000 | unchanged | 0.00 | ||
| SUPN | supernus pharmaceuticals inc | 5.50 | 313,499 | 15,581,000 | reduced | -13.75 | ||
| UTHR | united therapeutics corp | 15.71 | 91,282 | 44,477,000 | reduced | -6.52 | ||
| VNDA | vanda pharmaceuticals inc | 3.68 | 1,180,390 | 10,411,000 | unchanged | 0.00 | ||
| avadel pharmaceuticals | 6.52 | 855,860 | 18,444,000 | reduced | -10.46 | |||
| indivior plc | 4.30 | 339,532 | 12,182,000 | unchanged | 0.00 | |||